The beauty-meets-wellness industry has witnessed significant growth, reaching a combined value of $6.8 trillion. A key compound in this sector, peptides, found in various products ranging from injections to affordable lip balms, is under scrutiny. Researchers at Northeastern University have raised concerns about the accelerated use of peptides, questioning their safety and efficacy. This follows a meeting held by the U.S. Food and Drug Administration (FDA) to discuss the future of certain peptide compounds. Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services (HHS), has been an advocate for these compounds.
The debate centers on whether peptides, marketed for their abilities to enhance appearance and health, are adequately researched and ready for widespread use. Despite their popularity, experts caution against trusting products lacking comprehensive evaluation.
Peptides and the Future of Biohacking and Wellness
Once considered niche terms, ‘biohacking’ and ‘longevity’ now form part of mainstream discussions on personal care, with peptides leading the trend. Compared to other innovative methods such as NAD infusions and DNA-coded skincare, peptides have garnered significant attention. In January, U.S.-based peptide searches surged to 10.1 million monthly, a fivefold increase since 2020. Approximately one in eight Americans currently use GLP-1 drugs, comprising FDA-approved peptides like Ozempic and Mounjaro. Teenagers, influenced by these trends, reportedly prioritize their appearance more than previous generations.
The momentum might increase if the FDA decides to relax restrictions on peptide drugs, which remain under-studied according to agency scientists. On July 23, the Pharmacy Compounding Advisory Committee evaluated evidence to possibly expand access to peptides previously prohibited, allowing pharmacies to prescribe customized peptide formulations.
Emily G. Hilliard, HHS press secretary, explained to Newsweek that the FDA convened the committee to assess evidence regarding peptide benefits, risks, and safety. Based on the committee’s recommendations, the FDA will consult the United States Pharmacopeia and other sources to draft a proposed rule for public comment.
In February, Kennedy Jr. had proposed removing 14 of 19 banned peptides from the restricted list—an unprecedented shift in peptide regulation history.
Valerie Aparovich, a certified cosmetologist and biochemist from OnSkin, remains optimistic about peptides. She noted that topical peptides such as Matrixyl and Argireline support collagen production and have a high safety profile. However, she cautioned that evidence often originates from manufacturers rather than independent studies.
Why Are Some Experts Worried?
Amid enthusiasm from industry leaders and users, rare incidents highlight potential dangers. In 2025, authorities investigated severe illnesses following unauthorized peptide injections at a Las Vegas festival. Karthik Achari, founder of PepMD, presented concerns at the FDA meeting noting anecdotes abound while controlled data lacks, emphasizing the need for a regulated pathway over the current gray-market status.
Dr. Neil Panchal, chief medical officer of Longevitix, echoed Achari’s sentiments, stressing that when peptides are unavailable through licensed channels, consumers resort to unverified sources.
Professor Mansoor Amiji of Northeastern University was more skeptical, highlighting that aside from a few FDA-approved peptides like GLP-1 agonists and collagen supplements, many ‘hyped’ peptides lack preclinical and clinical validation. Influencers often claim peptides aid in faster recovery, performance improvement, and aging deceleration. However, Amiji warns of risks including systemic absorption even with topical use, contrasting with Aparovich’s safer view.
Steve Kates commented on the essential conditions for peptide approval, including efficacy validation, manufacturing standards, and toxicology assessment, emphasizing that current products haven’t met these standards.
This update incorporates additional details provided by Newsweek editors Kara Dolman and Emma Lee-Sang.